Key Highlights

  • Absci shares fell 10.17% on October 30, 2026.
  • No company-specific news was identified for the day.
  • Absci plans to report third-quarter results on November 12, 2026.
  • The company uses AI and generative design to discover antibody drug candidates.

Absci (NASDAQ:ABSI) fell 10.17% on Friday, but a search of news dated October 29 and 30 turned up no company-specific announcement. The most recent company item found was a notice that Absci plans to report third-quarter 2026 results on November 12, so the stock went into Friday with no fresh results or clinical readout to react to. The decline is best explained by a broad risk-off mood in growth and AI-linked stocks on the last trading day of October.

At the Intersection of Two Risky Themes

Absci is a biotechnology company that uses artificial intelligence and generative design to discover and develop antibody-based drug candidates. That puts it at the intersection of early-stage drug development, where value depends on future trial outcomes, and AI, where enthusiasm has driven valuations across sectors. On a day when the market shed AI-related themes, a development-stage company with no approved products was vulnerable regardless of its own news flow.

The Sell-Off Spread

The selling began with Intel (NASDAQ:INTC), whose weak fourth-quarter forecast sparked a semiconductor sell-off that spilled into software, cloud and AI hardware names. The S&P 500 fell 140.32 points, or 1.8%, to 7,580.07 and the Nasdaq Composite dropped 747.73 points, or 2.9%, to 25,437.00, as Intel's weak outlook triggered a chip rout and Amazon (NASDAQ:AMZN)'s results revived worries about AI spending. A market strategist summed up the mood by saying strong AI Demand is no longer enough on its own.

Rates Matter to Early-Stage Biotech

Federal Reserve officials said rates may need to go higher, and futures priced a strong chance of a December hike, while US midterm elections on November 3 add another source of uncertainty. Early-stage biotech companies typically rely on Capital Markets and their valuations are weighted toward distant cash flows, so tighter policy tends to hit them harder than established drugmakers, which held up better on Friday.

The November 12 Update

With no company news behind the drop, the next meaningful catalyst appears to be the scheduled November 12 update. Investors will look for pipeline progress, Partnership developments with larger drug companies and details on cash runway.